AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06195540
Drug: Rivaroxaban 10 MG
RxNorm normalized name: rivaroxaban 10 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of rivaroxaban 10 mg once daily to prevent venous thromboembolic events in patients with trauma to a lower limb.~Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose is rivaroxaban 10 mg orally once a day (no dosage adjustment).~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician.
Trial: NCT00000836
Drug: Sevirumab
RxNorm normalized name: Sevirumab
DrugBank: Sevirumab (DB17771)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04746547
Drug: Dolutegravir 50 MG
RxNorm normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twice daily dolutegravir with rifampicin containing TB treatment
Trial: NCT04746547
Drug: Dolutegravir 10 MG
RxNorm normalized name: dolutegravir 10 MG
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twice daily dolutegravir with rifampicin containing TB treatment
Trial: NCT05532618
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levobupivacaine
Trial: NCT06794008
Drug: BCMA-CD19 CAR-T therapy
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received the BCMA-CD19-targeted CAR-T cells with a dosage of 3×10\^6/kg CAR-T cells per kilogram.
Trial: NCT04662723
Drug: Sodium-glucose cotransporter 2 inhibitor
RxNorm normalized name: glucose / sodium chloride
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To reduce the progression of renal damage in IgAN Patients
Trial: NCT04939623
Drug: Probenecid
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Investigators aim to recruit 40 participants who will be followed for 12 weeks in duration. Participants will be randomized in a 2:2:1 ratio to one of probenecid 500 mg, 1000 mg, or placebo PO BID for 12 weeks. Justification for use of a non-active placebo comparator includes the fact that this trial is meant to identify tolerability and safety of probenecid in a population of patients living with chronic pain, this will be best measured by comparing to a non-active placebo.
Trial: NCT05552729
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were given vitamin D supplementation 48 hours after surgery, and the two groups were given different doses of vitamin D supplementation until the postoperative discharge criteria were met. To scientifically evaluate the application effect of early postoperative vitamin D intervention in the improvement of perioperative cognitive function in patients with gastrointestinal tumors.
Trial: NCT06048874
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
Trial: NCT06048874
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
Trial: NCT04231266
Drug: ManNAc
RxNorm normalized name: MANNAC
DrugBank: N-acetylmannosamine (DB12536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral N-acetyl-D-mannosamine monohydrate (ManNAc)
Trial: NCT04770246
Drug: TAS-117
RxNorm normalized name: TAS-117
DrugBank: TAS-117 (DB15054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-117 will be dosed orally every day on a 21-day cycle
Trial: NCT04770246
Drug: TAS-117
RxNorm normalized name: TAS-117
DrugBank: TAS-117 (DB15054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-117 will be dosed intermittently on a 21-day cycle
Trial: NCT04770246
Drug: TAS-117
RxNorm normalized name: TAS-117
DrugBank: TAS-117 (DB15054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
Trial: NCT05764642
Drug: Definity
RxNorm normalized name: Definity
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound contrast agent administered intravenously
Trial: NCT05406206
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.
Trial: NCT05859009
Drug: Non-Selective Beta Blockers (Propanolol)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
Trial: NCT04769895
Drug: MaaT013
RxNorm normalized name: MaaT013
DrugBank: MaaT013 (DB18648)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MaaT013 is made of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota
Trial: NCT05969119
Drug: Pyridostigmine
RxNorm normalized name: Pyridostigmine
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive either 60 mg oral Pyridostigmine every 6 hours or Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
Trial: NCT04728217
Drug: Efmoroctocog Alfa Injection [Eloctate]
RxNorm normalized name: efmoroctocog alfa Injection [Eloctate]
DrugBank: Efmoroctocog alfa (DB11607)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Efmoroctocog alfa should be administered according to Summary of Product Characteristics (SmPC)/ Instruction on Medical Use approved by Russian Ministry of Health ЛП-006034 (13.01.2020).
Trial: NCT03015844
Drug: 131-I-meta-iodobenzylguanidine
DrugBank: Guanidine (DB00536)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04877132
Drug: olipudase alfa (GZ402665)
RxNorm normalized name: olipudase alfa
DrugBank: Olipudase alfa (DB12835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive intravenous (IV) infusion of olipudase alfa
Trial: NCT05132088
Drug: semaglutide 50 mg
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will have semaglutide for 68 weeks and will have 1 tablet every morning.~Dose gradually increased to 50 mg.
Trial: NCT06654050
Drug: alrizomadlin
RxNorm normalized name: Alrizomadlin
DrugBank: Alrizomadlin (DB17549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alrizomadlin (APG-115) oral tablets (150 mg) taken every other day on Days 1, 3, 5, 7, 9, 11, and 13 of every cycle (1 cycle=21 days) for 8 cycles (i.e., Course 1). Individuals with stable or responding disease may receive an additional 8 cycles (i.e., Course 2). Maximum (total) of 2 treatment courses.
Trial: NCT06203600
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00000811
Drug: Atovaquone
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000811
Drug: Sulfamethoxazole-Trimethoprim
RxNorm normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06206512
Drug: Extended release torsemide
RxNorm normalized name: Torsemide
DrugBank: Torasemide (DB00214)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an extended-release formulation of torsemide
Trial: NCT06206512
Drug: Immediate release torsemide
RxNorm normalized name: Torsemide
DrugBank: Torasemide (DB00214)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is the generic, immediate release formulation of torsemide
Trial: NCT06206512
Drug: Extended release torsemide placebo
RxNorm normalized name: Torsemide
DrugBank: Torasemide (DB00214)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo of extended release torsemide
Trial: NCT06206512
Drug: Immediate release torsemide placebo
RxNorm normalized name: Torsemide
DrugBank: Torasemide (DB00214)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo of immediate release torsemide
Trial: NCT00793377
Drug: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
Trial: NCT00793377
Drug: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
Trial: NCT05899621
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT05899621
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide PO will be administered as per the schedule specified in the respective arm.
Trial: NCT05899621
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT05899621
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT05899621
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Trial: NCT05362760
Drug: Abemaciclib + Aromatase Inhibitor
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
Trial: NCT05362760
Drug: Abemaciclib + Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
Trial: NCT06516965
Drug: Povorcitinib
RxNorm normalized name: Povorcitinib
DrugBank: Povorcitinib (DB18855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06127407
Drug: Ivosidenib 500mg
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Provided as tablets, taken orally as two 250mg tablets once daily.
Trial: NCT06241742
Drug: HT-6184
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, oral dose of HT-6184
Trial: NCT06241742
Drug: HT-6184 Placebo
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, oral dose of placebo
Trial: NCT04681248
Drug: DKN-01
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion
Trial: NCT06220604
Drug: JNJ-77242113
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-77242113 will be administered orally.
Trial: NCT06220604
Drug: Deucravacitinib
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib will be administered orally.
Trial: NCT06220604
Drug: Deucravacitinib Matching Placebo
RxNorm normalized name: Deucravacitinib
DrugBank: AVAC (DB05441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib matching placebo will be administered orally.
Trial: NCT05263388
Drug: REKOVELLE (Follitropin Delta)
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE was 15 μg fixed for the first four stimulation days. Dose adjustments could be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, could occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose could be increased or decreased by 5 μg based on the participant's response. The minimum REKOVELLE dose was 5 μg and the maximum REKOVELLE was 20 μg. Participants could be treated for a maximum of 20 days.
Trial: NCT05438043
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab will be administered either intravenously or subcutaneously.
Trial: NCT05438043
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib will be administered intravenously.
Trial: NCT05438043
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered either orally or intravenously.
Trial: NCT05438043
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be administered orally.
Trial: NCT05438043
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide will be administered orally.
Trial: NCT05161143
Drug: Donafenib
RxNorm normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,patients will receive TACE once.
Trial: NCT05223868
Drug: JNJ-77242113
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-77242113 tablet will be administered orally.
Trial: NCT04978272
Drug: Dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duo-Cotecxin 20mg/160mg tabs by Holley-Cotec, Beijing, China Each treatment with DP will consist of half-strength tablets given once a day for 3 consecutive days according to weight-based guidelines.
Trial: NCT05066308
Drug: CBD
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring. The drug is formulated from extracts prepared from Cannabis sativa L. plants that have a defined chemical profile and contain consistent levels of CBD as the principal phytocannabinoid. Extracts from these plants are processed to yield pure (\>95%) CBD that typically contains less than 0.5% (w/w) THC. Cannabidiol is the active ingredient in Epidiolex; inactive ingredients include dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose. Of note, CBD has no psychoactive properties.
Trial: NCT06204614
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be placed in reservoir 2 of the implantable microdevice.
Trial: NCT06204614
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab will be placed in reservoir 3 of the implantable microdevice.
Trial: NCT06204614
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be placed in reservoir 4 of the implantable microdevice.
Trial: NCT06204614
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinblastine will be placed in reservoir 5 of the implantable microdevice.
Trial: NCT06204614
Drug: Gemcitabine/Cisplatin I
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine/Cisplatin will be placed in reservoir 6 of the implantable microdevice.
Trial: NCT06204614
Drug: Gemcitabine/Cisplatin II
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine/Cisplatin will be placed in reservoir 8 of the implantable microdevice.
Trial: NCT06204614
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin will be placed in reservoir 9 of the implantable microdevice.
Trial: NCT06204614
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be placed in reservoir 10 of the implantable microdevice.
Trial: NCT06204614
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be placed in reservoir 11 of the implantable microdevice.
Trial: NCT06204614
Drug: Gemcitabine/Carboplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine/Carboplatin will be placed in reservoir 12 of the implantable microdevice.
Trial: NCT06204614
Drug: Gemcitabine/Cisplatin/Nivolumab
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (Gemcitabine/Cisplatin/Nivolumab) will be placed in reservoir 14 of the implantable microdevice.
Trial: NCT06204614
Drug: Erdafitinib
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erdafitinib will be placed in reservoir 15 of the implantable microdevice.
Trial: NCT06204614
Drug: Paclitaxel/Docetaxel/Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (Paclitaxel/Docetaxel/Ifosfamide) will be placed in reservoir 16 of the implantable microdevice.
Trial: NCT06204614
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be placed in reservoir 17 of the implantable microdevice.
Trial: NCT06204614
Drug: Gemcitabine/Carboplatin/Nivolumab
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (Gemcitabine/Carboplatin/Nivolumab) will be placed in reservoir 18 of the implantable microdevice.
Trial: NCT06204614
Drug: Enfortumab
RxNorm normalized name: enfortumab
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enfortumab will be placed in reservoir 19 of the implantable microdevice.
Trial: NCT06204614
Drug: Sacituzumab
RxNorm normalized name: sacituzumab
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacitzumab will be placed in reservoir 20 of the implantable microdevice.
Trial: NCT06284486
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT06284486
Drug: Revumenib
RxNorm normalized name: Revumenib
DrugBank: Revumenib (DB18515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT01048983
Drug: Armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
Trial: NCT01048983
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
Trial: NCT01048983
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
Trial: NCT04498871
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib is recommended to be administered orally on a continuous schedule at a dose of 400 mg twice daily. The patient should be instructed to take each morning dose of nilotinib 2 hours after a light breakfast (e.g., toast and jam), with no oral intake other than water for 1 hour after dosing. It is recommended that the patient take nilotinib doses every 12 hours with a glass of water. The evening dose of nilotinib should be taken at least 2 hours after dinner with no oral intake other than water for 1 hour after dosing.
Trial: NCT06411210
Drug: Semaglutide Pen Injector
RxNorm normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Escalated to 2.4mg or max tolerated dose